Imai, Hisao <br/><br/>
Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.  [electronic resource] 

 -  Thoracic cancer  12 2019 
 - 2200-2208 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1759-7714 
<br/><br/><label>Standard No.: </label>10.1111/1759-7714.13193  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--diagnosis<br/>ErbB Receptors--antagonists & inhibitors<br/>Exons<br/>Female<br/>Humans<br/>Lung Neoplasms--diagnosis<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Mutation<br/>Neoplasm Staging<br/>Prognosis<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--pharmacology<br/>Treatment Outcome